The first agreement is with Cellerant Therapeutics which gives ONK exclusive rights to a humanized C-type lectin domain family 12 member A (CLEC12A) single-chain variable fragment (scFv) binder. ONK plans to combine CLEC12A chimeric antigen receptor (CAR) with a tumor necrosis factor (TNF)-related apoptosis-inducing ligand variant targeting death receptor 4; it will be used in patients with acute myeloid leukemia.

Under the second agreement, ONK will license a humanized, tumor-specific antibody targeting an aberrantly glycosylated tumor-associated form of MUC1 from Glycotope and will integrate this antibody into its preclinical program for solid tumors.

Finally, ONK is licensing a CC-chemokine receptor 7 (CCR7) homing receptor from the U.S. National Institutes of Health (NIH) for use in its preclinical program for relapsed/refractory B-cell cancer.

Glycostem licenses Ghent tech to advance NK cell therapies
Glycostem Therapeutics and Ghent University have signed a license agreement for natural killer (NK) cell production technology, with the goal of producing...

ImmunityBio touts preclinical data on NK cell therapy boosting product
ImmunityBio has released preclinical data demonstrating that its lead cytokine infusion protein, Anktiva, an interleukin-15 "superagonist," improves interferon-gamma...

Pluristyx supports Kiadis' COVID-19 NK cell therapy
Pluristyx will be supporting Kiadis Pharma and the Advanced Regenerative Manufacturing Institute's BioFabUSA program by providing services for the research...

Maps of natural killer cells offer insight into COVID-19 immune response
New research that sought to classify immune white blood cells, called natural killer cells, during COVID-19 infection revealed that certain cellular subtypes...

Companies work to develop combo mAb, NK cell COVID-19 therapy
A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal...